Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Boston Scientific to Buy Asthmatx

September 20, 2010 8:22 am | News | Comments

Boston Scientific will buy privately held Asthmatx Inc. in a deal that could be worth more than $440 million, the medical device maker said.


Researchers Find Key to HIV Drug Resistance

September 20, 2010 8:19 am | News | Comments

Rutgers researchers have discovered how HIV-1, the virus that causes AIDS, resists AZT, a drug widely used to treat AIDS.


Biological Clock Linked to Diabetes

September 20, 2010 8:16 am | News | Comments

Biologists have found that a key protein that regulates the biological clocks of mammals also regulates glucose production in the liver and that altering the levels of this protein can improve the health of diabetic mice.


BMS And AstraZeneca Diabetes Drug Reduces HbA1c

September 20, 2010 8:10 am | News | Comments

Bristol-Myers Squibb Company and AstraZeneca announced that a randomized, double blind Phase 3 clinical study demonstrated that the addition of dapagliflozin to existing glimepiride therapy produced significant reductions in HbA1c in adult patients with type 2 diabetes compared to glimepiride alone.


Harbor BioSciences Recieves Triolex Patent

September 20, 2010 8:05 am | News | Comments

Harbor BioSciences, Inc. announced that the company has received patent No. 7,776,845 from the United States Patent and Trademark Office which covers its lead metabolic disease and anti-inflammation drug candidate Triolex (HE3286).


FDA Explores Actos Cancer Link

September 20, 2010 8:02 am | by Matthew Perrone | News | Comments

The Food and Drug Administration is reviewing data suggesting a possible link between the widely used diabetes medication Actos and bladder cancer.


Spirivia As Good As Serevent

September 20, 2010 8:00 am | by Alicia Chang | News | Comments

Researchers say they've found a possible new treatment for adults with hard-to-control asthma. Their discovery, however, came at a price.


CEDRA Corporation Changes Name

September 20, 2010 7:51 am | News | Comments

Operating as a division of Worldwide Clinical Trials over the past three years, CEDRA Corporation announces its new company name, Worldwide Clinical Trials Drug Development Solutions.


Finding the Right Formula

September 20, 2010 7:22 am | by Rita C. Peters, Editorial Director | Articles | Comments

Like other sectors of the drug discovery and development process, drug formulation and drug delivery research has been challenged with finding effective and economical routes to bringing a drug to its target.


Scintillation Cocktail

September 17, 2010 9:07 am | Product Releases | Comments

SafeScint 1:1 from LabLogic Systems is a scintillation cocktail for discrete sample counting with a biodegradable formulation and outstanding counting efficiency with a high sample uptake capacity that saves on both consumption and disposal.


Rapid Microbiology System

September 17, 2010 9:04 am | Product Releases | Comments

Pall Corporation announced the introduction of the GeneDisc Rapid Microbiology System for advanced microbial quality monitoring. This system represents Pall’s latest quality assurance innovation for the pharmaceutical manufacturing industry.


CDI Partnering With ACEA on Cardiotoxicity

September 17, 2010 8:54 am | News | Comments

Cellular Dynamics International (CDI) announced their partnership with ACEA Biosciences to bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.


Head of Recall-Plagued J & J Division Resigns

September 17, 2010 8:51 am | by Linda A. Johnson | News | Comments

The head of the Johnson & Johnson division responsible for most of the company's 11 product recalls announced her retirement, shortly after a congressional committee probing the recalls invited her to a second hearing on the case.


GSK to Focus on Subcutaneous Delivery of Ofatumumab

September 17, 2010 8:46 am | News | Comments

After review of the program's full development strategy, GSK will focus development efforts on the subcutaneous delivery of ofatumumab in autoimmune indications and will stop further development work on the intravenous route of administration in autoimmune disease.


Scripps Researching Next-Gen DNA Sequencing

September 17, 2010 8:39 am | News | Comments

Scripps Research Institute has been awarded grant by the National Institutes of Health to help develop the next generation of DNA sequencing technologies, which could enable biomedical researchers and health care workers to routinely sequence a person’s DNA.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.